Tourette’s Syndrome THC CBD

Tourette’s Syndrome THC CBD

About this clinical trial

The purpose of the study is to evaluate an investigational product containing two compounds derived from the cannabis plant. These compounds are called tetrahydrocannabinol (THC) and cannabidiol (CBD). We are evaluating whether these compounds reduce tic severity and frequency in Tourette’s Syndrome (TS), as well as whether they reduce co-existing depressive, anxiety and obsessive-compulsive symptoms, which commonly affect people with TS.

The study will assess whether THC and CBD is well-tolerated and if it is associated with an improvement in quality of life.

Patients Required

Estimated completion

Follow-up completed 2022

Total participants required

Closed to recruitment

Study location

The Wesley Hospital

Trial title

A Randomised, Double Blind, Placebo-controlled, Crossover Trial of Tetrahydrocannabinol and Cannabidiol for the treatment of Tourette’s syndrome


Eligibility criteria:

  • Male or female volunteers aged 18 to 70 years of age
  • History of Tourette’s Syndrome with minimum total tic score of 20 out of 50
  • Healthy as assessed by medical history

Additional information

You can find out more about the THC CBD trial by visiting the ClinicalTrials.gov website.

Lead investigator

Dr Philip Mosley

If you would like more information about this clinical trial, please complete the Tourette's Syndrome THC CBD contact form


Wesley Medical Research

Scroll to Top